The Emerging Role of Liquid Biopsies in Lymphoproliferative Disorders

被引：5

作者：

Crombie, Jennifer ^{[1
]}

Armand, Philippe ^{[1
]}

机构：

[1] Dana Farber Canc Inst, Boston, MA 02115 USA

来源：

CURRENT HEMATOLOGIC MALIGNANCY REPORTS | 2019年 / 14卷 / 01期

关键词：

Liquid biopsy; Cell-free DNA; Lymphoma; Lymphoproliferative disorders; Minimal residual disease; MANTLE-CELL LYMPHOMA; MINIMAL RESIDUAL DISEASE; CIRCULATING TUMOR DNA; PROGRESSION-FREE SURVIVAL; PREVIOUSLY UNTREATED PATIENTS; POSITRON-EMISSION-TOMOGRAPHY; STAGE HODGKINS LYMPHOMA; FOLLICULAR LYMPHOMA; PROGNOSTIC VALUE; FOLLOW-UP;

D O I：

10.1007/s11899-019-0493-y

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Purpose of the ReviewLymphomas represent clinically and molecularly heterogeneous diseases with variable presentations, treatment algorithms, and outcomes. As treatment options continue to expand, more sophisticated prognostic and predictive biomarkers are needed to guide personalized treatment approaches.Recent FindingsLiquid biopsies, in which the sequencing of circulating tumor DNA (ctDNA) in peripheral blood serves as a surrogate for a tumor biopsy, are now being studied across cancer subtypes, including in lymphoid malignancies. Recent studies have demonstrated the potential of these techniques to improve prognostication and guide individualized treatment strategies, providing a significant advance in the field of precision medicine.SummaryIn this review, we describe the sequencing platforms currently available for analysis of ctDNA in lymphoma and their potential applications in clinical practice, which seem poised to refine treatment paradigms across lymphoma subtypes.

引用

页码：11 / 21

页数：11

共 76 条

[1] Observation as the initial management strategy in patients with mantle cell lymphoma [J].

Abrisqueta, P. ;

Scott, D. W. ;

Slack, G. W. ;

Steidl, C. ;

Mottok, A. ;

Gascoyne, R. D. ;

Connors, J. M. ;

Sehn, L. H. ;

Savage, K. J. ;

Gerrie, A. S. ;

Villa, D. .

ANNALS OF ONCOLOGY, 2017, 28 (10) :2489-2495

[2] Scalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumors [J].

Adalsteinsson, Viktor A. ;

Ha, Gavin ;

Freeman, Samuel S. ;

Choudhury, Atish D. ;

Stover, Daniel G. ;

Parsons, Heather A. ;

Gydush, Gregory ;

Reed, Sarah C. ;

Rotem, Denisse ;

Rhoades, Justin ;

Loginov, Denis ;

Livitz, Dimitri ;

Rosebrock, Daniel ;

Leshchiner, Ignaty ;

Kim, Jaegil ;

Stewart, Chip ;

Rosenberg, Mara ;

Francis, Joshua M. ;

Zhang, Cheng-Zhong ;

Cohen, Ofir ;

Oh, Coyin ;

Ding, Huiming ;

Polak, Paz ;

Lloyd, Max ;

Mahmud, Sairah ;

Helvie, Karla ;

Merrill, Margaret S. ;

Santiago, Rebecca A. ;

O'Connor, Edward P. ;

Jeong, Seong H. ;

Leeson, Rachel ;

Barry, Rachel M. ;

Kramkowski, Joseph F. ;

Zhang, Zhenwei ;

Polacek, Laura ;

Lohr, Jens G. ;

Schleicher, Molly ;

Lipscomb, Emily ;

Saltzman, Andrea ;

Oliver, Nelly M. ;

Marini, Lori ;

Waks, Adrienne G. ;

Harshman, Lauren C. ;

Tolaney, Sara M. ;

Van Allen, Eliezer M. ;

Winer, Eric P. ;

Lin, Nancy U. ;

Nakabayashi, Mari ;

Taplin, Mary-Ellen ;

Johannessen, Cory M. .

NATURE COMMUNICATIONS, 2017, 8

[3]

[Anonymous], BLOOD

[4] Hodgkin lymphoma: 2016 update on diagnosis, risk-stratification, and management [J].

Ansell, Stephen M. .

AMERICAN JOURNAL OF HEMATOLOGY, 2016, 91 (04) :434-442

[5] Rituximab versus a watch-and-wait approach in patients with advanced- stage, asymptomatic, non-bulky follicular lymphoma: an open-label randomised phase 3 trial [J].

Ardeshna, Kirit M. ;

Qian, Wendi ;

Smith, Paul ;

Braganca, Nivette ;

Lowry, Lisa ;

Patrick, Pip ;

Warden, June ;

Stevens, Lindsey ;

Pocock, Christopher F. E. ;

Miall, Fiona ;

Cunningham, David ;

Davies, John ;

Jack, Andrew ;

Stephens, Richard ;

Walewski, Jan ;

Ferhanoglu, Burhan ;

Bradstock, Ken ;

Linch, David C. .

LANCET ONCOLOGY, 2014, 15 (04) :424-435

[6] A phase 2 study of Rituximab-Bendamustine and Rituximab-Cytarabine for transplant-eligible patients with mantle cell lymphoma [J].

Armand, Philippe ;

Redd, Robert ;

Bsat, Jad ;

Mayuram, Sangeetha ;

Giardino, Angela ;

Fisher, David C. ;

LaCasce, Ann S. ;

Jacobson, Caron ;

Davids, Matthew S. ;

Brown, Jennifer R. ;

Weng, Li ;

Wilkins, Jennifer ;

Faham, Malek ;

Freedman, Arnold S. ;

Joyce, Robin ;

Jacobsen, Eric D. .

BRITISH JOURNAL OF HAEMATOLOGY, 2016, 173 (01) :89-95

[7] Liquid Biopsies, What We Do Not Know (Yet) [J].

Bardelli, Alberto ;

Pantel, Klaus .

CANCER CELL, 2017, 31 (02) :172-179

[8] A phase II multicenter trial of hyperCVAD MTX/Ara-C and rituximab in patients with previously untreated mantle cell lymphoma; SWOG 0213 [J].

Bernstein, S. H. ;

Epner, E. ;

Unger, J. M. ;

LeBlanc, M. ;

Cebula, E. ;

Burack, R. ;

Rimsza, L. ;

Miller, T. P. ;

Fisher, R. I. .

ANNALS OF ONCOLOGY, 2013, 24 (06) :1587-1593

[9] Minimal residual disease detection in mantle cell lymphoma: methods and significance of four-color flow cytometry compared to consensus IGH-polymerase chain reaction at initial staging and for follow-up examinations [J].

Boettcher, Sebastian ;

Ritgen, Matthias ;

Buske, Sebastian ;

Gesk, Stefan ;

Klapper, Wolfram ;

Hoster, Eva ;

Hiddemann, Wolfgang ;

Unterhalt, Michael ;

Dreyling, Martin ;

Siebert, Reiner ;

Kneba, Michael ;

Pott, Christiane .

HAEMATOLOGICA, 2008, 93 (04) :551-559

[10] Non-invasive monitoring of diffuse large B-cell lymphoma by cell-free DNA high-throughput targeted sequencing: analysis of a prospective cohort [J].

Bohers, Elodie ;

Viailly, Pierre-Julien ;

Becker, Stephanie ;

Marchand, Vinciane ;

Ruminy, Philippe ;

Maingonnat, Catherine ;

Bertrand, Philippe ;

Etancelin, Pascaline ;

Picquenot, Jean-Michel ;

Camus, Vincent ;

Menard, Anne-Lise ;

Lemasle, Emilie ;

Contentin, Nathalie ;

Lepretre, Stephane ;

Lenain, Pascal ;

Stamatoullas, Aspasia ;

Lanic, Helene ;

Libraire, Julie ;

Vaudaux, Sandrine ;

Pepin, Louis-Ferdinand ;

Vera, Pierre ;

Tilly, Herve ;

Jardin, Fabrice .

BLOOD CANCER JOURNAL, 2018, 8

← 1 2 3 4 5 6 7 8 →